The Central Drug Standards Control Organization (CDSCO) has granted license to Biolumpivaxin -- the country’s first vaccine ...

BioViva’s journey in gene therapy began with its use of an adeno-associated virus (AAV) vector. The company ... immunogenicity make it redosable in animal models (Fig. 1).